Payment overview · 2025
General Payments
$1,059.89
44 reported records · 10 companies
Healthcare provider profile · identity verified
Dallal W Abdelsayed, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HIGHLANDS, TX · NPI 1649345216
Verified facts
What the public records show
CMS Open Payments records show Dallal W Abdelsayed, M.D. received $1,059.89 in general payments during 2025 across 44 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 29.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Otezla, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Otezla by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $312.80 | 29.5% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $281.34 | 26.5% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.73 | 18.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $127.50 | 12.0% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.76 | 3.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.29 | 2.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $21.34 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.36 | 1.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.97 | 1.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.80 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,059.89 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $312.80 | 10 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $281.34 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $143.20 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $130.52 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $129.17 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $127.50 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.04 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.76 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 72 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
72 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 115 |
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 117 |
| Lisinopril | Lisinopril | 277 | 84 |
| Gabapentin | Gabapentin | 274 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 258 | 85 |
| Metformin Hcl | Metformin Hcl | 253 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 72 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 230 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 79 |
| Losartan Potassium | Losartan Potassium | 193 | 60 |
| Alprazolam | Alprazolam | 188 | 37 |
| Furosemide | Furosemide | 186 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 55 |
| Azithromycin | Azithromycin | 165 | 113 |
| Simvastatin | Simvastatin | 162 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 159 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 154 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 45 |
| Glimepiride | Glimepiride | 139 | 41 |
| Meloxicam | Meloxicam | 130 | 55 |
| Tramadol Hcl | Tramadol Hcl | 125 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 120 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 114 | 37 |
| Omeprazole | Omeprazole | 111 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 33 |
| Trazodone Hcl | Trazodone Hcl | 105 | 40 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 93 | 68 |
| Eliquis | Apixaban | 92 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 27 |
| Lorazepam | Lorazepam | 74 | 23 |
| Sertraline Hcl | Sertraline Hcl | 74 | 20 |
| Ozempic | Semaglutide | 72 | 17 |
| Potassium Chloride | Potassium Chloride | 71 | 27 |
| Naproxen | Naproxen | 70 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 29 |
| Januvia | Sitagliptin Phosphate | 68 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 21 |
| Montelukast Sodium | Montelukast Sodium | 67 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 24 |
| Farxiga | Dapagliflozin Propanediol | 65 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 20 |
| Clindamycin Hcl | Clindamycin Hcl | 61 | 37 |
| Donepezil Hcl | Donepezil Hcl | 61 | 21 |
| Clonidine Hcl | Clonidine Hcl | 57 | 16 |
| Synthroid | Levothyroxine Sodium | 57 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 38 |
| Finasteride | Finasteride | 56 | suppressed |
| Jardiance | Empagliflozin | 56 | 15 |
| Atenolol | Atenolol | 55 | 18 |
| Carvedilol | Carvedilol | 55 | 19 |
| Diazepam | Diazepam | 55 | suppressed |
| Nifedipine Er | Nifedipine | 52 | 15 |
| Cefuroxime | Cefuroxime Axetil | 50 | 37 |
| Allopurinol | Allopurinol | 47 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Celecoxib | Celecoxib | 43 | 16 |
| Solifenacin Succinate | Solifenacin Succinate | 43 | 13 |
| Methylprednisolone | Methylprednisolone | 42 | 33 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Pregabalin | Pregabalin | 39 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 38 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 36 | 11 |
| Meclizine Hcl | Meclizine Hcl | 35 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 13 |
| Clonazepam | Clonazepam | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 11 |
| Levetiracetam | Levetiracetam | 34 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 13 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Mupirocin | Mupirocin | 32 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | 13 |
| Ibuprofen | Ibuprofen | 30 | 18 |
| Linzess | Linaclotide | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 28 | 20 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 16 |
| Trulicity | Dulaglutide | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 24 | suppressed |
| Prednisone | Prednisone | 23 | 14 |
| Valsartan | Valsartan | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 11 |
| Sucralfate | Sucralfate | 22 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Desloratadine | Desloratadine | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 16 |
| Amoxicillin | Amoxicillin | 16 | 11 |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 15 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Otezla | Apremilast | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,059.89 · 44 records | Bayer Healthcare Pharmaceuticals Inc. | AIRSUPRA, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, Veozah, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error